Stayzon™ plus Bacitracin

Market Size – US: $50 million (Operating Room segment)
Worldwide: $100 million

Our independent lab compared our product, Stayzon™ + Bacitracin, to the market leader Bacitracin Ointment. In vitro results showed Stayzon™ + Bacitracin provided a superior barrier to bacterial growth compared to Bacitracin Ointment. Stayzon™ + Bacitracin is the only product in the world that keeps a bandage in place and delivers antibiotic to protect the surgical site area.

TEST RESULTS

Results expressed as breakthrough growth under skin (g) or no breakthrough
growth (0)

Test Agent

Microorganism

Replicates

1 2 3 4 5 6

Stayzon™
plus
Bacitracin

Staphylococcus aureus

0

0

0

g

0

0

Staphylococcus epidermidis

0

0

0

0

0

0

Enterococcus faecalis

0

0

0

0

0

0

Streptococcus pyogenes

0

0

0

0

0

0

Bacitracin
Ointment

Staphylococcus aureus

0

g

g

0

g

g

Staphylococcus epidermidis

0

0

g

0

0

g

Enterococcus faecalis

g

g

0

g

g

0

Streptococcus pyogenes

0

g

0

g

g

0

Mastisol

Staphylococcus aureus

g

g

g

g

g

g

Staphylococcus epidermidis

g

g

g

g

g

g

Enterococcus faecalis

g

g

g

g

0

g

Streptococcus pyogenes

g

0

g

g

g

g

75%
Ethanol

Staphylococcus aureus

g

g

g

g

g

g

Staphylococcus epidermidis

g

g

g

g

g

g

Enterococcus faecalis

g

g

g

g

g

g

Streptococcus pyogenes

g

g

g

g

g

g

ART has a 5% royalty deal to distribute its post-operative topical product (Mastisol® Plus) in the $100M U.S. surgical adhesive marketplace until 2033. The product will be launched in North America by the licencee in 2016.